Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s lead product candidate, FX-322, is a potential disease modifying therapy designed to regenerate auditory hair cells to improve hearing function. Two clinical studies in which a single dose of FX-322 was administered have shown statistically significant and clinically meaningful improvements in speech intelligibility. In addition, FX-322 was observed to be well-tolerated with no serious adverse effects. The Frequency progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue and the company is researching an array of additional degenerative diseases where PCA may be applied, including a discovery program in multiple sclerosis.
Annual Report and Proxy Statement
May 6, 2021 10:00 PM EDT
Data Provided by Refinitiv. Minimum 15 minutes delayed.